Cancers, Vol. 13, Pages 5162: Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer

Cancers, Vol. 13, Pages 5162: Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer Cancers doi: 10.3390/cancers13205162 Authors: Sicong Hou Ziyin Pan Xin Hao Qinglei Hang Yanbing Ding Neoadjuvant therapies, primarily chemotherapy and chemoradiotherapy, are able to improve the overall survival (OS) in patients with locally advanced resectable esophageal cancer (EC) based on the results of several randomized clinical trials. The advantage of neoadjuvant therapy is chiefly attributed to the decreased risk of local–regional recurrence and distant metastasis. Thus, it has been recommended as standard treatment for patients with resectable EC. However, several fundamental problems remain. First, the combination of neoadjuvant chemotherapy (nCT), neoadjuvant chemoradiotherapy (nCRT), and surgery for EC patients with different histological types remains controversial. Furthermore, to reduce the toxicity of preoperative chemotherapy and the risk of complications caused by preoperative radiation therapy, the treatment protocols of nCT and nCRT still need to be investigated and optimized by prospective trials. Moreover, for patients with complete clinical response following neoadjuvant therapy, it is worth ascertaining whether a “watch and wait” surveillance plus surgery-as-needed policy is more favorable, as well as, in addition to preoperative chemoradiotherapy, whether immunotherapy, especially when combined with the tradi...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research